JAV-Raras: Comparative Analysis of Patient’s Costs According to Clinical and Therapeutic Protocol (PCDT) and Current Clinical Practice for Osteogenesis Imperfecta (OI) in Brazilian Public Healthcare System
Author(s)
Azevedo C1, Souza JS1, Gargano L2, Salvador BC3, Ogata G4, Félix T5, Nita ME1, JAV-Raras Study Group P1
1MAPESolutions, São Paulo, PR, Brazil, 2MAPESolutions, São Paulo, SP, Brazil, 3MAPESolutions, Curitiba, PR, Brazil, 4MAPESolutions, SÃO PAULO, SP, Brazil, 5Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
Objective: Clinical and therapeutic protocol (PCDT) are intended to provide disease-specific rules for healthcare practitioners. We assess if the costs of care defined by the Osteogenesis Imperfecta (OI) PCDT reflects the costs of current clinical practice (CCP) conducted in Brazilian medical centers, using Time-Driven Activity-Based Costing (TDABC) method. Methods: The “Value of Healthcare Journey for Patients With Rare Diseases Project” (JAV-Raras) is a nationwide cohort study aggregated with cost assessment through TDABC. Patients' journeys were mapped for OI patients’ CCP in each medical center and for the established care in the PCDT, elaborated and updated in 2013 by the Brazilian Ministry of Health (MoH). Costs charged by medical centers were inputted in CCP TDABC allowing direct comparison with clinical practice. Results: We analyzed data from three medical centers from diferentes regions of Brazil ( South, North, and Southeast). Cost of a OI patients’ one-year journey was USD 2,430.74, USD 4,973.49, and USD 1,183.18 for CCP, while costs for PCDT were USD 1,712.17, USD 1,913.57, and USD 1,310.73 in South, North, and Southeast, respectively. We found a difference of USD 718.57, USD 3,059.92 and USD -127.56 in the costs according to CCP, in comparison to the PCDT. When assessing the moment in the patient's journey, treatment costs were higher for all medical centers, while follow-up was the most expensive in CCP. Conclusion: Costs incurred by current clinical practice in the medical centers are greater than the costs outlined in the PCDT, suggesting that patients with OI have unattended needs by the PCDT and reflecting the need of an update. Declaration of funding: This study was funded by the National Council for Scientific and Technological Development – CNPq and the Ministry of Health of Brazil – MoH.
Conference/Value in Health Info
2022-05, ISPOR 2022, Washington, DC, USA
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Code
HSD110
Topic
Economic Evaluation, Epidemiology & Public Health, Patient-Centered Research, Study Approaches
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes, Prospective Observational Studies, Public Health
Disease
No Additional Disease & Conditions/Specialized Treatment Areas